Phathom Pharma Upgraded by Barclays to Overweight $18 Target
Barclays lifts Phathom Pharmaceuticals to Overweight with an $18 target, citing a stronger 2026 revenue trajectory an...
Understanding which assets have the highest returns can guide your investment strategy. Explore various options to enhance your portfolio.
25,689 articlesBarclays lifts Phathom Pharmaceuticals to Overweight with an $18 target, citing a stronger 2026 revenue trajectory an...
AMD posted a blowout Q1 FY2026 with record revenue and booming data-center sales. The company guides stronger-than-ex...
Barclays lifts Atlassian price target to $112, signaling growing confidence in the company’s ARR trajectory and enter...
As gasoline prices stay stubbornly high, Americans are cutting driving and postponing trips to protect household budg...
A civil social-media debate this spring highlighted a looming fight over who will own payments: Visa or on-chain stab...
The Department of Homeland Security is requesting $7.5 million to develop wearable facial-recognition glasses for ICE...
Malaysian authorities reveal Iranian-linked vessels are swapping sanctioned oil in offshore zones near Johor, raising...
When a rising rapper faced a life-or-death verdict, the courtroom moment captured the nation. But beyond the headline...
Arbor Homes launches its Arrival Series in Louisville, debuting homes from $199,995 to tackle rising housing costs. T...
A surge in AI-focused hardware stocks has lifted semiconductors, yet traders warn that the moment when semi trade tur...
Grab is moving to pilot a new delivery robot in Singapore’s Punggol district by late 2026, aiming to relieve labor sh...
Rising gas costs push Gen Z to curb discretionary spending, nudging cosmetics brands to cut prices and rethink produc...